There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

BioMarin Pharmaceutical Inc. has a 12 month low of $60.63 and a 12 month high of $94.85. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors in BioMarin Pharmaceutical Inc (Symbol: BMRN) saw new options become available this week, for the October 17th expiration. One of the key data points that goes into the price an option ...

How Do Unusual Items Influence Profit? To properly understand BioMarin Pharmaceutical's profit results, we need to consider the US$86m expense attributed to unusual items. It's never great to see ...

The occasion was the 2025 PRWeek Healthcare Awards, a celebration of the sector that crafts the public’s perception of pharmaceutical ... banner emblazoned with logos of corporate sponsors.